ADMA BioCenters
ADMA BioCenters operates ten FDA-licensed plasma collection centers across six southeastern U.S. states, collecting source plasma from compensated donors via automated plasmapheresis for its parent company ADMA Biologics (NASDAQ: ADMA) to manufacture immune globulin therapies.
- Company typePrivate
- Founded2009
- HeadquartersRoswell, United States
- Headcount51–100
- GTM typeB2C
- OfferingServices
What ADMA BioCenters does
ADMA BioCenters is a U.S. specialty plasma collection operator that runs a network of FDA-licensed plasmapheresis centers. Founded in 2009 and headquartered in Roswell, Georgia, the company employs between 251 and 500 people and operates ten plasma donation centers across six southeastern states (Georgia, South Carolina, Tennessee, Louisiana, Maryland, and North Carolina). Its core service is collecting human source plasma from compensated individual donors; the underlying technology is automated plasmapheresis, which separates plasma from red blood cells and returns the red cells to the donor with saline replacement, performed with single-use disposable collection equipment. Supporting products include the Donor ADvantage online pre-screening and QR-code check-in platform, designed to shorten returning-donor visit time, and the Buddy Bonus referral program, which pays donors for each successful referral.
The company's revenue model is transaction-based: donors are paid per successful plasma collection, typically via a prepaid debit card, with compensation varying by location, donor status (new versus returning), and promotional programs. Go-to-market is direct-to-consumer, executed through the company website, paid and organic social channels (LinkedIn, Facebook, Instagram), HubSpot-managed call-to-action funnels, and donor referral incentives. Customers are individual adults aged 18–65 residing within roughly 50 miles of a center; the end-beneficiaries of the collected plasma are patients with immune deficiencies, burn and trauma injuries, hemophilia, alpha-1 antitrypsin deficiency, and other conditions treatable with plasma-derived immunoglobulins.
ADMA BioCenters operates as a wholly owned subsidiary of ADMA Biologics, Inc. (NASDAQ: ADMA), a publicly traded biopharmaceutical company that manufactures immune globulin products. The vertical integration provides a guaranteed offtake channel for collected plasma into the parent's manufacturing operations, and BioCenters itself reports no independent funding, no external investors, and no publicly disclosed standalone revenue. The company is certified under FDA 21 CFR Part 820, follows cGMP and CDC protocols, and is positioned as a regulated, regionally concentrated feedstock supplier within its parent's plasma therapeutics supply chain.
ADMA BioCenters firmographics
Firmographics- Name
- ADMA BioCenters
- Legal name
- ADMA BioCenters Georgia, Inc.
- Website
- https://admabiocenters.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- ADMA BioCenters operates ten FDA-licensed plasma collection centers across six southeastern U.S. states, collecting source plasma from compensated donors via automated plasmapheresis for its parent company ADMA Biologics (NASDAQ: ADMA) to manufacture immune globulin therapies.
- Ownership category
- akta.pro rank
ADMA BioCenters industry classification
Industry- Product category
- Plasma Collection Services
- NAICS
- Blood and Organ Banks (621991)
- akta.pro primary industry
- Plasma Collection & Donor Services (Plasmapheresis Centers) (HLAIAHAH)
Keywords
Where ADMA BioCenters is headquartered
LocationHeadquarters
- HQ city
- Roswell
- HQ country
- United States
- HQ region
- North America
Offices10 records
Markets served
ADMA BioCenters business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- Plasma Collection Services: ADMA BioCenters collects human plasma from donors at their FDA-licensed facilities. The plasma collected is used by parent company ADMA Biologics to manufacture immune globulin products for treating immunodeficiency and other conditions. Donors receive compensation for each successful plasma donation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Per-donation compensation for plasma donors |
| Other | Pay-as-you-go | New donor loyalty bonus program |
| Other | Pay-as-you-go | Buddy Bonus referral program |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
ADMA BioCenters product offering
Product offeringCore offering
ADMA BioCenters operates a network of FDA-licensed plasma donation centers across the southeastern United States, where it collects human plasma from compensated donors via automated plasmapheresis. The collected plasma is supplied to its parent company, ADMA Biologics, Inc., for use in manufacturing immune globulin therapies and other plasma-derived medications for patients with immune deficiencies and rare diseases.
Product overview
ADMA BioCenters operates a network of FDA-licensed plasma collection facilities across multiple U.S. states. The core service is plasma donation, where donors contribute plasma used to manufacture life-saving biologics and immunoglobulins for patients with immune deficiencies, burns, hemophilia, and other plasma protein deficiencies. The company offers Donor ADvantage, an online pre-screening questionnaire platform for returning donors, alongside the Buddy Bonus referral program. All facilities follow cGMP standards and FDA compliance regulations.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Donors can donate up to 2 times within a 7-day period
- +1 more outcomes
Companies that use ADMA BioCenters
Customer profileSegments2 records
Ideal customer profiles1 record
ADMA BioCenters technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ADMA BioCenters partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ADMA BiologicscoreADMA BioCenters is a wholly owned subsidiary of ADMA Biologics, Inc. The collected plasma is used by ADMA Biologics to manufacture immune globulin products for treating immunodeficiency disorders and other conditions. This vertical integration ensures a guaranteed market for collected plasma.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
ADMA BioCenters competitors and assessment
Company assessmentDirect peers
- BPL Plasma: U.S. plasma collection network affiliated with Bio Products Laboratory (BPL), a fractionator of plasma-derived therapies. Operates a multi-state network of FDA-licensed centers that compete with ADMA BioCenters for the same donor pool and supply an integrated parent manufacturer.
- Grifols: Operates one of the world's largest plasma collection networks (over 350 centers) supplying its own fractionation business. Highly comparable to ADMA BioCenters: vertically integrated plasma collector + fractionator, FDA-licensed U.S. footprint, donor compensation-based model.
- Kedrion Biopharma: Plasma-derived therapy manufacturer that operates plasma collection centers in the U.S. (including through the former KedPlasma network) to feed its fractionation operations. Directly comparable as a vertically integrated collector-frationator with a U.S. donor-pay model.
- BioLife Plasma Services: U.S. plasma collection business owned by Takeda, operating more than 200 centers nationwide. Direct competitor for donors in ADMA BioCenters' southeastern markets, and supplies plasma fractionated (in part) for Takeda's immunoglobulin and other plasma-derived products.
- CSL Plasma: Largest plasma collection network globally, operated as a division of CSL Behring. Operates hundreds of FDA-licensed centers across the U.S. and supplies source plasma to CSL Behring's fractionation operations, making it the closest direct peer to ADMA BioCenters in terms of model (donor-pay collection centers feeding a vertically integrated parent).
- Octapharma Plasma: U.S. subsidiary of Octapharma AG, operating 180+ plasma donation centers across the U.S. Captive supplier of plasma to Octapharma's fractionation operations, with the same donor-pay / vertically-integrated model as ADMA BioCenters.
Regional players
- Vitalant: One of the largest nonprofit blood and plasma collection organizations in the U.S., operating donor centers across multiple states. Comparable in donor-recruitment and FDA-regulated collection operations, though it is a nonprofit and focuses more on whole blood and Source plasma for transfusion use, with a regional rather than nationwide presence.
- Sanquin Plasma: Dutch blood and plasma collector (part of Sanquin Blood Supply) operating plasma collection centers primarily in the Netherlands and Europe. Comparable as a non-U.S. regulated plasma collector feeding a fractionation operation, but does not directly compete with ADMA BioCenters in the U.S. southeastern donor market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
ADMA BioCenters social profiles
Digital presenceADMA BioCenters compliance and trust
Trust signalCompliance1 record
ADMA BioCenters financial estimates
Financial estimateRevenue estimate
Valuation estimate
ADMA BioCenters leadership team
Management profileNumber of profiles
ADMA BioCenters funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ADMA BioCenters M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ADMA BioCenters
What does ADMA BioCenters do?
ADMA BioCenters operates a network of FDA-licensed plasma donation centers across the southeastern United States, where it collects human plasma from compensated donors via automated plasmapheresis. The collected plasma is supplied to its parent company, ADMA Biologics, Inc., for use in manufacturing immune globulin therapies and other plasma-derived medications for patients with immune deficiencies and rare diseases.
Is ADMA BioCenters a public or private company?
ADMA BioCenters is a private company. It is classified as corporate owned and is currently operating.
When was ADMA BioCenters founded?
ADMA BioCenters was founded in 2009. It employs 51 to 100 people.
Where is ADMA BioCenters based?
ADMA BioCenters is headquartered in Roswell, United States, in the North America region.
How does ADMA BioCenters make money?
One revenue line is on record: plasma Collection Services.
Who are ADMA BioCenters's main competitors?
Direct peers on record are BPL Plasma, Grifols, Kedrion Biopharma, BioLife Plasma Services, CSL Plasma and Octapharma Plasma. Regional players are Vitalant and Sanquin Plasma.
Does ADMA BioCenters have an API?
No public API is recorded for ADMA BioCenters.
What industry is ADMA BioCenters in?
ADMA BioCenters's product category is Plasma Collection Services. Its primary akta.pro industry code is HLAIAHAH, Plasma Collection & Donor Services (Plasmapheresis Centers). Its NAICS code is 621991.